Futura Medical PLC Block Listing Applications to AIM (6215O)
01 Febrero 2023 - 7:26AM
UK Regulatory
TIDMFUM
RNS Number : 6215O
Futura Medical PLC
01 February 2023
1 February 2023
Futura Medical plc
("Futura" or the "Company")
Block Listing Applications to AIM
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, announces application
has been made to AIM for a block listing of 4,444,942 ordinary
shares of 0.2 pence each in the Company ("Ordinary Shares"). This
will be used to facilitate the admission of shares to trading
following the exercise of options granted under the Company's LTIP
Scheme as announced on 12 January 2023.
Additionally, an application has been made to the London Stock
Exchange to extend the Company's existing block listings by a total
of 1,100,000 Ordinary Shares which may arise pursuant to the
exercise of options under the Company's EMI Share Option
Scheme.
The Ordinary Shares will be issued from time to time pursuant to
the Company's existing plans including outstanding options already
issued but not yet exercised to the employees of the Company.
Ordinary Shares issued following option exercises and admitted to
trading under the block admission will rank pari passu in all
respects with the existing Ordinary Shares.
The block listing is expected to become effective on 2 February
2023. The Company will make six-monthly announcements of the
utilisation of the block admission, in line with its obligations
under AIM Rule 29.
At the time of this announcement, the Company has 288,133,957
ordinary shares in issue, each carrying one voting right. Since the
Company currently holds no shares in treasury, the total number of
voting rights in the Company is therefore 288,133,957 and this
figure may be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance
and Transparency Rules.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction ("ED") through a
unique evaporative mode of action. Futura has previously conducted
a Phase 3 study using MED3000 in ED, referred to as "FM57". This
was a 1,000 patient, dose-ranging, multi-centre, randomised, double
blind, placebo-controlled, home use, parallel group study
delivering highly statistically significant results compared to
pre-treatment baseline, using measures IIEF-EF, SEP2 and SEP3
(internationally accepted clinical trial endpoints in ED) with over
60% of patients experiencing a clinically meaningful improvement in
their ED.
MED3000 is CE marked in Europe and CA marked in the UK as a
clinically proven topical treatment for adult men with erectile
dysfunction under the brand Eroxon(TM) with a key claim of "Helps
you get an erection within 10 minutes".
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSUAUOROSUURAR
(END) Dow Jones Newswires
February 01, 2023 08:26 ET (13:26 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024